View Cart  

Canada Looks to Boost Rare Disease Research Via Orphan Drug Pathway

A A
Health Canada is developing a new approval pathway for orphan drugs as part of an effort to spur development of drugs for conditions that affect less than five in 10,000 patients.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor

Buy This Article Now

Add this article to your cart for $40.00